These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29091313)

  • 1. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
    Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
    Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice.
    Gumuslu E; Mutlu O; Celikyurt IK; Ulak G; Akar F; Erden F; Ertan M
    Fundam Clin Pharmacol; 2016 Aug; 30(4):376-84. PubMed ID: 26935863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas.
    Gezginci-Oktayoglu S; Bolkent S
    Biochem Cell Biol; 2009 Aug; 87(4):641-51. PubMed ID: 19767827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
    Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
    Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
    Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
    J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CTRP3, a novel adipokine, in rats at different pathogenic stages of type 2 diabetes mellitus and the impacts of GLP-1 receptor agonist on it.
    Li X; Jiang L; Yang M; Wu YW; Sun SX; Sun JZ
    J Diabetes Res; 2014; 2014():398518. PubMed ID: 25177707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
    Zheng YC
    Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.
    Gezginci-Oktayoglu S; Sacan O; Yanardag R; Karatug A; Bolkent S
    Peptides; 2011 Feb; 32(2):223-31. PubMed ID: 21055431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
    Jia Y; Gong N; Li TF; Zhu B; Wang YX
    Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.
    Yang G; Lei Y; Inoue A; Piao L; Hu L; Jiang H; Sasaki T; Wu H; Xu W; Yu C; Zhao G; Ogasawara S; Okumura K; Kuzuya M; Cheng XW
    Atherosclerosis; 2017 Sep; 264():1-10. PubMed ID: 28734203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
    Ozyazgan S; Kutluata N; Afşar S; Ozdaş SB; Akkan AG
    Pharmacology; 2005 Jun; 74(3):119-26. PubMed ID: 15746570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
    Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
    Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
    Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats.
    Solmaz V; Çınar BP; Yiğittürk G; Çavuşoğlu T; Taşkıran D; Erbaş O
    Eur J Pharmacol; 2015 Oct; 765():482-7. PubMed ID: 26386291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats.
    Habib HA; Heeba GH; Khalifa MMA
    Eur J Pharmacol; 2021 Feb; 892():173721. PubMed ID: 33159934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.
    Himeno T; Kamiya H; Naruse K; Harada N; Ozaki N; Seino Y; Shibata T; Kondo M; Kato J; Okawa T; Fukami A; Hamada Y; Inagaki N; Seino Y; Drucker DJ; Oiso Y; Nakamura J
    Diabetes; 2011 Sep; 60(9):2397-406. PubMed ID: 21810596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M; Bajaj M
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
    Chen T; Kagan L; Mager DE
    J Pharm Sci; 2013 Oct; 102(10):3844-51. PubMed ID: 23897494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
    Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
    J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.